Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Blood - Tập 113 Số 20 - Trang 4829-4833 - 2009
Giovanni Barosi1, Gunnar Birgegård2, Guido Finazzi3, Martin Grießhammer4, Claire Harrison5, Hans Carl Hasselbalch6, Jean‐Jacques Kiladjian7, Eva Lengfelder8, Mary Frances McMullin9, Francesco Passamonti10, John T. Reilly11, Alessandro M. Vannucchi12, Tiziano Barbui13
1Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;
2Department of Haematology, University Hospital, Uppsala, Sweden
3Division of Transfusion Medicine, Ospedali Riuniti di Bergamo, Bergamo, Italy;
4Department of Hematology and Oncology, Johannes Wesling Medical Centre Minden, Academic Hospital of the University of Hannover, Minden, Germany
5Department of Haematology, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom
6Department of Hematology L, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
7Assistance Publique-Hopitaux de Paris, Hopital Avicenne, Service d'Hematologie Clinique, Université Paris 13, Bobigny, France;
8Department of Medicine III, Faculty for Medicine Mannheim, University of Heidelberg, Heidelberg, Germany;
9Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom
10Division of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
11Molecular Haematology Unit, Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, United Kingdom;
12Unità Funzionale di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Università degli Studi, Firenze, Italy; and
13Division of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy

Tóm tắt

European experts were convened to develop a definition of response to treatment in polycythemia vera (PV) and essential thrombocythemia (ET). Clinicohematologic (CH), molecular, and histologic response categories were selected. In ET, CH complete response (CR) was: platelet count less than or equal to 400 × 109/L, no disease-related symptoms, normal spleen size, and white blood cell count less than or equal to 10 × 109/L. Platelet count less than or equal to 600 × 109/L or a decrease greater than 50% was partial response (PR). In PV, CH-CR was: hematocrit less than 45% without phlebotomy, platelet count less than or equal to 400 × 109/L, white blood cell count less than or equal to 10 × 109/L, and no disease-related symptoms. A hematocrit less than 45% without phlebotomy or response in 3 or more of the other criteria was defined as PR. In both ET and in PV, molecular CR was a reduction of any molecular abnormality to undetectable levels. Molecular PR was defined as a reduction more than or equal to 50% in patients with less than 50% mutant allele burden, or a reduction more than or equal to 25% in patients with more than 50% mutant allele burden. Bone marrow histologic response in ET was judged on megakaryocyte hyperplasia while on cellularity and reticulin fibrosis in PV. The combined use of these response definitions should help standardize the design and reporting of clinical studies.

Từ khóa


Tài liệu tham khảo

Tefferi, 2007, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel., Blood, 110, 1092, 10.1182/blood-2007-04-083501

Vannucchi, Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal., Leukemia, 2008, 1299

Beer, 2008, MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort., Blood, 112, 141, 10.1182/blood-2008-01-131664

Passamonti, 2006, Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders., Blood, 107, 3676, 10.1182/blood-2005-09-3826

Tefferi, 2008, JAK and MPL mutations in myeloid malignancies., Leuk Lymphoma, 49, 388, 10.1080/10428190801895360

Barbui, 2007, Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk., Semin Thromb Haemost, 33, 321, 10.1055/s-2007-976166

Trapp, 1998, Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count., Blood Cells Mol Dis, 24, 9, 10.1006/bcmd.1998.0166

Petitt, 1997, Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders., Semin Hematol, 34, 51

Steurer, 2004, Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile., Cancer, 101, 2239, 10.1002/cncr.20646

Randi, 2005, Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders., Haematologica, 90, 261

Jabbour, 2007, PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study., Cancer, 110, 2012, 10.1002/cncr.23018

Langer, 2005, Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study., Haematologica, 90, 1333

Samuelsson, 2006, Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia., Haematologica, 91, 1281

Harrison, 2005, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study: hydroxyurea compared with anagrelide in high-risk essential thrombocythemia., N Engl J Med, 353, 33, 10.1056/NEJMoa043800

Passamonti, 2000, Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients., Haematologica, 85, 1011

Silver, 2006, Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha., Cancer, 107, 451, 10.1002/cncr.22026

Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera., Blood, 112, 3065, 10.1182/blood-2008-03-143537

White, 1985, The clinical efficacy assessment project of the American College of Physicians., Int J Tech Assess Health Care, 1, 169, 10.1017/S0266462300003822

William, 1994, The Delphi technique: a methodological discussion., J Adv Nurs, 19, 180, 10.1111/j.1365-2648.1994.tb01066.x

Delbecq, 1975, Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes.

Thiele, 2007, Myelofibrosis—what's in a name? Consensus on definition and EUMNET grading., Pathobiology, 74, 89, 10.1159/000101708

Barosi, 2005, European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)., Blood, 106, 2849, 10.1182/blood-2005-04-1520

Barbui, 2004, Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation., Haematologica, 89, 215

McMullin, 2005, Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis., Br J Haematol, 130, 174, 10.1111/j.1365-2141.2005.05535.x

Di Nisio, 2007, The hematocrit and platelet target in polycythemia vera., Br J Haematol, 136, 249, 10.1111/j.1365-2141.2006.06430.x

Pearson, 1978, Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia., Lancet, 2, 1219, 10.1016/S0140-6736(78)92098-6

Spivak, 2001, Erythropoietin use and abuse: when physiology and pharmacology collide., Adv Exp Med Biol, 502, 207, 10.1007/978-1-4757-3401-0_14

Landolfi, 2004, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators: efficacy and safety of low-dose aspirin in polycythemia vera., N Engl J Med, 350, 114, 10.1056/NEJMoa035572

Ricksten, 2008, Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia., Haematologica, 93, 1260, 10.3324/haematol.12801

Thông tin
Thông tin xuất bản

Blood

Tập 113 Số 20

4829-4833

Thông tin tác giả